Zenas BioPharma, Inc. Common Stock Net Asset Momentum
Zenas BioPharma, Inc. Common Stock net asset momentum. Zenas BioPharma, Inc. Common Stock (ZBIO) recorded a net asset momentum of -22.5% as of December 2025, with net assets of $242.14 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Check cash flow reinvestment rate of Zenas BioPharma, Inc. Common Stock to assess the company's total reinvestment commitment from operating cash flow.
YoY Momentum
Current Net Assets
Years of Data
Country
Net Asset Momentum of Zenas BioPharma, Inc. Common Stock (2022–2025)
Net asset momentum of Zenas BioPharma, Inc. Common Stock from 2022 to 2025. This chart tracks Zenas BioPharma, Inc. Common Stock's year-over-year net asset growth across 4 annual reporting periods from 2022 to 2025. The most recent momentum reading is -22.5%, with net assets of $242.14 Million USD as of December 2025. See Zenas BioPharma, Inc. Common Stock net assets for net asset value and shareholders' equity analysis.
Zenas BioPharma, Inc. Common Stock Net Asset Momentum by Year (2022–2025)
Zenas BioPharma, Inc. Common Stock net asset momentum by year from 2022 to 2025. The table below shows the complete annual net asset history for Zenas BioPharma, Inc. Common Stock from 2022 to 2025, covering 4 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see market cap of Zenas BioPharma, Inc. Common Stock.
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | $242.14 Million | $383.64 Million | $141.50 Million | ▼ -22.5% |
| 2024 | $312.46 Million | $369.97 Million | $57.51 Million | ▲ +238.4% |
| 2023 | $-225.72 Million | $68.18 Million | $293.90 Million | ▼ -17.4% |
| 2022 | $-192.29 Million | $74.58 Million | $266.87 Million | — |